We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals

107 hedge funds and large institutions have $210M invested in Rigel Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 42 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

8.92% more ownership

Funds ownership: 0%8.92% (+8.9%)

12% less funds holding

Funds holding: 121107 (-14)

23% less call options, than puts

Call options by funds: $202K | Put options by funds: $262K

26% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 42

33% less capital invested

Capital invested by funds: $316M → $210M (-$105M)

48% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 27

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
107
Holders Change
-14
Holders Change %
-11.57%
% of All Funds
2.67%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
14
Increased
31
Reduced
42
Closed
27
Calls
$202K
Puts
$262K
Net Calls
-$60K
Net Calls Change
-$2.04M
Name Holding Trade Value Shares
Change
Change in
Stake
Jane Street
126
Jane Street
New York
-$40K -1,082 Closed
PHK
127
Point72 Hong Kong
Hong Kong
-$26K -720 Closed
Simplex Trading
128
Simplex Trading
Illinois
-$14.2K -497 Closed
AIM
129
Acrospire Investment Management
Illinois
-$9K -246 Closed
Bank of Montreal
130
Bank of Montreal
Ontario, Canada
-$6K -150 Closed
RFA
131
Reilly Financial Advisors
California
+$573 +20 New

RIGL Hedge Fund Activity: Q4 2016 in Review

107 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2016, worth a combined $210M — down 33% from $316M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of RIGL and 14 opened new positions — a net loss of 13 holders — while 42 trimmed existing stakes and 31 added.

The largest buyer was Wellington Management Group, adding an estimated $16.5M. The largest seller was Boxer Capital, exiting entirely with an estimated $4.96M sold.

  • 107 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2016, down from 121 in Q3 2016.
  • Funds reported $210M of Rigel Pharmaceuticals stock for Q4 2016, down 33% quarter-over-quarter.
  • 14 funds opened new Rigel Pharmaceuticals positions in Q4 2016 and 27 closed out, a net change of -13 holders.
  • The largest Rigel Pharmaceuticals buyer in Q4 2016 was Wellington Management Group, an estimated $16.5M added.
  • The largest Rigel Pharmaceuticals seller in Q4 2016 was Boxer Capital, an estimated $4.96M sold.

Based on aggregated 13F filings for Q4 2016.